慢性阻塞性肺疾病三联用药定量吸入剂的研究现状被引量：11

Research status of inhaler triple therapy for chronic obstructive pulmonary disease

导出

摘要慢性阻塞性肺疾病(COPD)是常见的慢性呼吸系统疾病,患病率高,疾病负担重,且无法完全治愈。吸入激素/长效β受体激动药/长效抗胆碱能药(ICS/LABA/LAMA)三药联合治疗相比于ICS/LABA或LAMA单药治疗,可改善患者的肺功能、症状和健康状况,减少急性加重的发生。三联治疗可提高用药依从性和疗效,但不易调整单一组份的剂量。本文旨在为今后临床合理应用该类型吸入剂提供参考。 Chronic obstructive pulmonary disease（ COPD） is a common chronic respiratory system disease that could not be cured,and the prevalence and cost of which is high. Triple inhaled therapy of inhaled corticosteroid/long-acting β2-agonist/long-acting bronchodilators（ ICS/LABA/LAMA） improves lung function,symptoms and health status and reduces exacerbations compared to ICS/LABA or LAMA monotherapy.Single-inhaler combination of ICS/LABA/LAMA can improve patient compliance and efficacy. However,it＇s hard to change the specific dose of one single compound through a single-inhaler combination of three compounds. This review aimed to provide information for the rational clinical use of the single inhaler of triple therapy in the future.

作者李静姿周颖崔一民

机构地区北京大学第一医院药剂科

出处《中国临床药理学杂志》 CAS CSCD 北大核心 2017年第21期2199-2201,2205,共4页 The Chinese Journal of Clinical Pharmacology

关键词慢性阻塞性肺疾病三联疗法吸入激素/长效β受体激动药/长效抗胆碱能药 chronic obstructive pulmonary disease triple therapy inhaled corticosteroid/ long - acting β2 agonist /long acting bronchodilators

分类号 R97 [医药卫生—药品]

引文网络
相关文献

参考文献2

1郭海英,周新.新抗胆碱能药物格隆溴铵[J].上海医药,2013,34(15):10-12. 被引量：10
2马凌悦,阙呈立,田硕涵,周颖,孙刘阳,崔一民.临床药师干预对慢性阻塞性肺疾病患者吸入剂使用技术和自我管理的影响[J].中国临床药理学杂志,2016,32(17):1569-1571. 被引量：38

二级参考文献14

1Zhong N, Wang C, Yao W, et al. Prevalence of chronicobstructive pulmonary disease in China: a large, population- based survey [J]. Am J Respir Crit Care Med, 2007, 176(8): 753-760.
2GOLD Executive Committee. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease (Revised 2011) [EB/OL]. [2013-01-13]. http://www.goldcopd.org/uploads/users/files/ GOLD Reoort 2011 Feb21.ndf.
3European Medicines Agency. Seebri Breezhaler - Summary of Product Characteristics [EB/OL]. [2013-02-10]. http:// www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_ Product_Information/human/002430/WC500133769.pdf.
4D'Urzo A, Ferguson GT, van Noord JA, et al. Efficacy and safety of once-daily NVA237 in patients with moderate-to- severe COPD: the GLOWI trial [J]. Respir Res, 2011, 12: 156.
5Kerwin E, H6bert J, Gallagher N, et al. Efficacy and safety of NVA237 versus placebo and tiotropium in patients with moderate-to-severe COPD over 52 weeks: the GLOW2 study [J]. Eur Respir J, 2012, 40(5): 1106-1114.
6Beeh KM, Singh D, Di Scala L, et al. Once-daily NVA237 improves exercise tolerance from the first dose in patients with COPD: the GLOW3 trial [J]. Int J COPD, 2012, 7(1): 503-513.
7Gupta P, Mahony MS. Potential adverse effects of bronchodilators in the treatment of airways obstruction in older people: recommendations for prescribing [J]. Drugs Aging, 2008, 25(5): 415-443.
8RABE K F, HURD S, ANZUETO A, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmo- nary disease: GOLD executive summary [ J ]. Am J Respir Crit (:are Med, 2007, 176(6) :532 -55.
9ZHONG H, NIX J, CU1 M, et al. Evaluation of pharmacist care for patients with chronic obstructive pulmonary disease: a systematic re'Tiew and meta -analysis[J]. Int J Clin Pharm, 2014~ 36(6) 1230 -- 1240.
10KHDOUR M R, KIDNEY J C, SMYTH B M, et al. Clinical phar- macy- led disease and medicine management programme for patient,~ with COPD [J] Br J Clin Pharmacol, 2009, 68(4) :588 --598.